Source: Annual Congress 2013 –COPD: new markers of diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kulynych-Miskiv, M. Ostrovskyy, O. Varunkiv, I. Savelikhina (Ivano-Frankivsk, Ukraine). Changes of IL-6 level in bronchoalveolar fluid in patients with acute exacerbation of COPD before and after the treatment with tiotropium bromide, and its significance. Eur Respir J 2013; 42: Suppl. 57, 601

Member's Comments

No comment yet.

Related content which might interest you: Changes of TNF-a level in bronchoalveolar fluid of patients with chronic obstructive pulmonary disease before and after the 30 days treatment with tiotropium bromide Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015 Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 Activation of MMP-9 in BAL is increased in COPD exacerbation independently of smoking, lung function, microbiology and treatment Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014 Change of induced sputum TNF-a and sTNF-R55,75 levels in patients with acute exacerbations of COPD Source: Annual Congress 2007 - Respiratory pathophysiology Year: 2007 Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Acute exacerbations in COPD patients are associated with increased levels of hyaluronic acid and heparan sulfate in BAL Source: International Congress 2014 – Translational studies in COPD Year: 2014 Pulmonary and systemic inflammation in patients with AECOPD Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Sputum VEGF level increases with treatment of COPD acute exacerbation Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation Year: 2012 Protective effects of tiotropium bromide on the morphological remodeling of the bronchi on the neocollagenesis processes in patients with moderate COPD during exacerbation Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Activin-A levels in sputum and serum of COPD, asthma and ACOS patients during acute exacerbation and at baseline Source: International Congress 2017 – Infection and exacerbation science Year: 2017 Diagnostic implications of sTREM-1 in induced sputum and BAL fluid of patients with asthma and COPD Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD Source: Eur Respir J 2007; 30: 472-478 Year: 2007 Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 The effect of inhaled corticosteroids on bronchoalveolar lavage interleukin-8 levels and cell percentage in stable chronic obstructive pulmonary disease patients Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 The influence of the COPD exacerbation treatment on the MMP-9 concentration in serum, induced sputum and BAL Source: Eur Respir J 2005; 26: Suppl. 49, 298s Year: 2005 Increased circulating alveolar epithelial microparticles in COPD patients Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013